DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Rhea-AI Summary

DBV Technologies (DBVT) held its 2025 Combined General Meeting, where shareholders approved all resolutions proposed by the Board of Directors. The meeting was presided over by Michel de Rosen, Chairman of the Company. The voting results and resolutions have been made available on the company's website in the Investors/Annual General Meetings section.

Châtillon, France, June 11, 2025

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

Shareholders approved all proposed resolutions

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.

The Company’s shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2025-annual-general-meeting/.

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Viaskin and EPIT are trademarks of DBV Technologies.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

What were the key outcomes of DBV Technologies' 2025 Combined General Meeting?

All resolutions proposed by the Board of Directors were approved by shareholders at the meeting.

Who chaired DBV Technologies' (DBVT) 2025 Combined General Meeting?

Michel de Rosen, Chairman of the Company, chaired the Combined General Meeting.

Where can investors find the voting results of DBV Technologies' 2025 annual meeting?

The voting results and resolutions are available on DBV Technologies' website under the Investors/Annual General Meetings section.

When did DBV Technologies (DBVT) hold its 2025 Combined General Meeting?

DBV Technologies held its Combined General Meeting on June 11, 2025.